Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 0.67 |
| ▸ | MAOB | P27338 | 9/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.54 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19596183 | 1.00 | KDM1A (0.67) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL7509163 | 0.93 | KDM1A (0.60) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL6991918 | 0.93 | KDM1A (0.60) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL31113844 | 0.93 | KDM1A (0.60) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL2837243 | 0.93 | KDM1A (0.60) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL7509170 | 0.93 | KDM1A (0.60) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL6991920 | 0.93 | KDM1A (0.60) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL2835482 | 0.93 | KDM1A (0.60) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL1570164 | 0.91 | KDM1A (0.61) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL2217941 | 0.91 | KDM1A (0.61) | KDM1AMAOBKCNH2RCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598480-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2019-04-24 | — | — | EP | claimed |
| US-9676701-B2 | Cyclopropylamine derivatives useful as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2017-06-13 | — | — | US | claimed |
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. | 2016-02-25 | — | — | US | claimed |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2013-08-01 | — | — | US | claimed |
| EP-2598480-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2013-06-05 | — | — | EP | claimed |
| WO-2012013727-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2012-02-02 | — | — | WO | claimed |
| EP-2598480-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2019-04-24 | — | — | EP | disclosed |
| US-9676701-B2 | Cyclopropylamine derivatives useful as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2017-06-13 | — | — | US | disclosed |
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. | 2016-02-25 | — | — | US | disclosed |
| US-9006449-B2 | Cyclopropylamine derivatives useful as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2015-04-14 | — | — | US | disclosed |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | ORYZON GENOMICS S.A. (ES) | 2013-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052865-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAOB 173/4885KCNH2 1391/4885 |
| US-20130197013-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAOB 173/4885KCNH2 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.